Skip to main content


A study of potential disease modifying treatments in individuals at risk for or with a type of early onset Alzheimer’s disease caused by a genetic mutation (DIAN-TU)

Washington University School of Medicine
Clinical Trial
Lecanemab & E2814

Information about the drugs that will be tested in the study

Name of the drugs

This study tests different drugs.

Current investigational products include lecanemab and E2814.

Investigation with solanezumab is now closed.

Investigation with gantenerumab is ongoing with an open label extension study, which enrolls participants of a previous clinical trial to continue to observe efficacy and measure long-term safety of gantenerumab


Gantenerumab is administered via a subcutaneous injection (an injection under the skin) every four weeks

Lecanemab and E2814 are administered via an intravenous infusion (an injection into the vein).

Is the drug already on the market for another medical condition?


Will all participants receive the same drug?

For the E2814 and lecanemab drugs, symptomatic participants will receive:

  • At Week 0, an intravenous infusion of lecanemab for the full treatment period
  • At Week 24, they will be selected by chance to receive an intravenous infusion of E2814 or placebo (also called a dummy treatment which is an inactive substance identical in appearance to the drug being tested with no active therapeutic effect) for the remainder of the treatment period. Neither the participant nor their doctor will know if the person is receiving E2814 or the placebo.

For the E2814 and lecanemab drugs, participants with normal cognition will receive:

  • At week 52, an intravenous infusion of E2814 or placebo for the full treatment period. Neither the participant nor their doctor will know if the person is receiving E2814 or the placebo.
  • At Week 24, they will receive an intravenous infusion of lecanemab for the remainder of the treatment period.

Information about participating in the trial

What are the researchers trying to find out?

The purpose of the study is to evaluate the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational drugs in people who are known to have an Alzheimer's disease-causing mutation.

How long will the treatment last?

Around 4 years

What your involvement will entail?

During the study, participants will have:

  • To undergo brain scan (PET, MRI) and lumbar punctures (CSF)
  • To complete tests that will assess memory and cognition.

Further information on the number of visits can be obtained from the study team.

Who can participate in this study?

Who can participate in the study?
  • Be between 18 and 80 years old
  • Have a genetic mutation that causes Alzheimer's disease or are a family member with a dominantly inherited Alzheimer's disease (DIAD) mutation (e.g. APP, PSEN1, PSEN2))
  • Have a score of 0-1 in the Clinical Dementia Rating-Global Score (CDR). This would suggest that the person has no or mild impairment in their memory
  • Females of childbearing potential must agree to use effective contraception if partner is not sterile
  • Have a study partner who has a sufficient contact with the participant, is willing to participate in study procedures throughout the study duration
Who cannot participate in the study?

People cannot take part in the study if they have or have experienced (main exclusion criteria):

  • Evidence of significant abnormality on brain MRI scans
  • Drug or alcohol abuse or dependence within the past year
  • Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin, or body which would prevent MRI scan
  • History or presence of significant cardiovascular disease, liver/kidney disorders, infectious disease, immune disorder or uncontrolled hypertension
  • History of cancer within the last 5 years
  • Positive pregnancy test or plans to become pregnant during the trial period.

The above list is not exhaustive. It includes the most common conditions and diseases that might exclude people from the study.

Information for your doctor

EudraCT Number

2013-000307-17 identifier


Study contact information

Link to full text

The information contained in this document is based on information available on public registries (e.g. website) in June 2024.


Alzheimer Europe's Clinical Trials Watch database was developed as part of the 2018 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).

Alzheimer Europe gratefully acknowledges the support of its corporate sponsors for the update and maintenance of the database.